Sung Ji Nam
Stock Analyst at Scotiabank
(2.57)
# 1,656
Out of 5,182 analysts
81
Total ratings
47.76%
Success rate
2.99%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $88.50 | -32.20% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $55.11 | +36.09% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $180.62 | +52.25% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $468.04 | +26.06% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $128.52 | -2.74% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $24.98 | +60.13% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $10.13 | +295.06% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $4.83 | +24.22% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.23 | +225.20% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.59 | +25.79% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $14.21 | -15.55% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $299.79 | +50.11% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $61.00 | +1.64% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $33.85 | +29.99% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $21.85 | +60.18% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $3.14 | +91.08% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.60 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $88.50
Upside: -32.20%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $55.11
Upside: +36.09%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $180.62
Upside: +52.25%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $468.04
Upside: +26.06%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $128.52
Upside: -2.74%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $24.98
Upside: +60.13%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $10.13
Upside: +295.06%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $4.83
Upside: +24.22%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.23
Upside: +225.20%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.59
Upside: +25.79%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $14.21
Upside: -15.55%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $299.79
Upside: +50.11%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $61.00
Upside: +1.64%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $33.85
Upside: +29.99%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $21.85
Upside: +60.18%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $3.14
Upside: +91.08%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $15.60
Upside: -